Immuneering Corporation (NASDAQ:IMRX) Short Interest Up 43.1% in December

Immuneering Corporation (NASDAQ:IMRX) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1% from the December 15th total of 7,635,854 shares. Based on an average trading volume of 1,780,211 shares, the short-interest ratio is presently 6.1 days. Currently, 21.9% of the shares of the company are short sold. Currently, 21.9% of the shares of the company are short sold. Based on an average trading volume of 1,780,211 shares, the short-interest ratio is presently 6.1 days.

Immuneering Stock Down 1.3%

Shares of IMRX stock traded down $0.06 during trading hours on Friday, reaching $4.58. The company’s stock had a trading volume of 1,571,991 shares, compared to its average volume of 3,135,325. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $10.08. The firm’s 50 day simple moving average is $6.37 and its 200-day simple moving average is $5.82. The company has a market capitalization of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Sell-side analysts predict that Immuneering will post -1.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IMRX. Oppenheimer raised their target price on shares of Immuneering from $21.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th. Leerink Partnrs raised Immuneering to a “strong-buy” rating in a research report on Friday, October 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Leerink Partners started coverage on Immuneering in a report on Friday, October 31st. They set an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $16.50.

Insider Buying and Selling

In other Immuneering news, Director Peter Feinberg purchased 20,000 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average cost of $4.35 per share, with a total value of $87,000.00. Following the completion of the transaction, the director owned 135,441 shares in the company, valued at $589,168.35. The trade was a 17.32% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought 24,924 shares of company stock worth $108,400 over the last 90 days. 22.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immuneering

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in Immuneering in the 1st quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Immuneering during the third quarter worth $35,000. Future Financial Wealth Managment LLC acquired a new position in shares of Immuneering during the third quarter worth $35,000. Kingsview Wealth Management LLC bought a new position in shares of Immuneering in the 2nd quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Immuneering in the 3rd quarter valued at $70,000. 67.65% of the stock is owned by institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.